What is Semax used for? In Russia, registered intranasal products have specific uses: acute ischemic stroke as part of combined hospital care, recovery and cognitive problems associated with vascular brain disease, and certain optic-nerve conditions. In the United States, people more often ask about focus, memory and mental stamina. Those nootropic uses have a much thinner human evidence base and are not established treatments for cognitive decline or ADHD.
The distinction matters. A foreign registration, a small human study and a consumer use are three different kinds of evidence.
What is Semax used for in Russia?
Russia has registered two intranasal concentrations with different labels. The 1% Russian prescribing information names moderate-to-severe acute ischemic stroke, with Semax used as one part of combination therapy. The broader 0.1% prescribing information covers intellectual and memory disorders associated with vascular brain damage, post-stroke recovery, transient cerebral circulation problems, and optic-nerve atrophy or neuritis.
| Context | What the Russian registration says | What it does not mean |
|---|---|---|
| Acute ischemic stroke | The 1% intranasal product is registered as an adjunct to combined care for moderate or severe stroke | It is not a substitute for emergency stroke treatment |
| Post-stroke and vascular cognitive problems | The 0.1% product includes recovery after stroke and intellectual-memory disorders tied to vascular brain disease | It is not a general indication for normal aging or everyday forgetfulness |
| Optic-nerve disease | The 0.1% product includes optic-nerve atrophy and inflammatory or toxic-allergic neuritis | It is not a general vision supplement |
| Mental strain | The 0.1% label includes prevention of mental fatigue during highly demanding or monotonous work | That label does not establish a broad cognitive-enhancement effect in healthy U.S. adults |
The clinical literature behind these uses is real but limited. A 1997 controlled study compared 30 people receiving Semax within intensive stroke care with 80 conventional-care controls and reported faster regression of some neurological deficits (Gusev et al., 1997). An optic-nerve study evaluated Semax alongside standard neurotrophic and anti-inflammatory care, not by itself, and reported changes in visual measures (Polunin et al., 2000). Both papers are older Russian studies, so they cannot carry the same weight as large, independently replicated modern trials.
The nootropic uses people ask about
Outside those registered clinical contexts, Semax is usually discussed as a nootropic for sustained attention, recall, mental clarity or demanding work. The strongest honest description is that these uses are being explored, not that they are established outcomes.
A small 1996 human paper reported EEG changes and better operator-task performance after intranasal Semax, with effects described over 20 to 24 hours (Kaplan et al., Neuroscience Research Communications). A later placebo comparison in 24 healthy volunteers found a change in resting-state brain-network topography after one intranasal exposure, but it measured imaging rather than memory, attention or everyday functioning (Lebedeva et al., 2018). A brain-network signal is not proof that a person will think more clearly.
For the molecular research, see how Semax works. For the narrower clinical question, Semax for ADHD explains why the available literature does not establish it as an ADHD treatment.
What the evidence can and cannot answer
The human evidence separates into two small lanes. One concerns people with neurological or optic-nerve disease, usually receiving other care at the same time. The other concerns short experiments in healthy volunteers, often measuring EEG, task performance or brain imaging. Neither lane tells us whether long-term use improves memory, prevents cognitive decline or changes school or work performance in a clinically meaningful way.
Route also limits what can be inferred. Russia's registered products and most human studies used intranasal Semax. Findings from those products do not automatically transfer to a different compounded formulation or route. There is also little long-term controlled human safety data. New memory problems, vision changes or stroke symptoms need diagnostic or emergency care appropriate to the symptom, not a nootropic interpretation.
Semax use and status in the United States
As of September 2026, Semax is approved in Russia. In the United States, it may be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA's 2026 review states that neither Semax free base nor Semax acetate is a component of an approved U.S. drug and documents their evaluation for the 503A bulk-substances list (FDA Semax briefing document). Review of a bulk ingredient for compounding is not approval of a finished drug and does not establish a clinical indication.
A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. Promise's current Semax-containing option is the compounded Semax / Selank blend, not standalone Semax. Semax versus Selank covers the difference, while what Selank is used for keeps the companion peptide's uses separate.
The practical way to read a Semax claim
A useful claim names the population, route and outcome. “Studied in stroke rehabilitation by the intranasal route” is specific. “Supports brain performance” is not. The same test applies to vendor language about focus or memory: ask whether the source measured a feeling, a validated cognitive outcome, an imaging change or a disease endpoint. Those results are not interchangeable.
For someone considering prescription care, the central question is whether the goal resembles anything measured in people and whether a more established evaluation should come first. The research can support a careful provider conversation. It cannot promise a cognitive result.